![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Weighs Lower Dosage for Moderna COVID-19 Booster Shot
FDA Weighs Lower Dosage for Moderna COVID-19 Booster Shot
![Moderna logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Moderna-logo.jpg?t=1589311392&width=430)
September 7, 2021
The FDA is deliberating between approving a booster shot of Moderna’s COVID-19 vaccine at a 50 microgram (mcg) level or at a current 100 mcg level, the latter being the level that make up the first two doses each of the vaccine.
Last week, Cambridge, Mass.-based Moderna announced that it has asked the FDA to evaluate the booster dose at the 50-mcg level. The vaccine is formally known as mRNA-1273.
The company said it expects to submit data to the European Medicines Agency and other international regulatory authorities in the coming days.
Upcoming Events
-
21Oct